AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO LEAD TESTING.
Summary
HB312 amends Delaware’s Childhood Lead Poisoning Prevention Act to broaden what counts as confirmatory blood lead testing for children under 16. Under current law, confirmation is tied to a venous blood lead test; this bill adds an alternative pathway allowing confirmation through two capillary blood screenings collected within 12 weeks of each other, so long as the applicable lead reference value is met or exceeded.
The bill is intended to make it easier to identify and manage elevated blood lead levels earlier in the process, while aligning Delaware’s statutory definition with CDC surveillance practice. The synopsis states that two properly collected positive capillary screenings have a very high effective specificity and that the change would reduce barriers to case identification and follow-up, while also requiring conforming regulatory updates.
Impact
The bill would amend Title 16, section 2601 of the Delaware Code by revising the definition of “testing” for purposes of the Childhood Lead Poisoning Prevention Act. It expands the legal basis for a confirmed elevated blood lead level from venous testing alone to include two qualifying capillary screenings, which affects how public health officials, clinicians, and laboratories document and confirm lead exposure in children under 16. The change would also require related regulations and administrative procedures to be updated to match the new statutory standard.
Sentiment
The available voting history suggests the bill was broadly supported in the House, passing third reading 37-1. No committee transcript is available, but the near-unanimous vote and the bill’s public health framing indicate generally favorable sentiment. The stated purpose—reducing barriers to lead case identification and aligning with CDC guidance—also suggests the measure was viewed as a technical and preventive health update rather than a controversial policy shift.
Contention
The main policy issue is the shift away from requiring venous blood testing as the only confirmatory method. Supporters appear to favor the added flexibility because it can speed identification and reduce barriers to follow-up care, especially when capillary screenings already indicate elevated lead levels. Any opposition likely centers on the reliability of capillary testing compared with venous testing, though the bill’s synopsis addresses that concern by citing the high specificity of two positive capillary screenings and limiting the alternative to two tests within a defined time window.